

COURTESY TRANSLATION


THE SPOKEN WORD IS VALID



Dear shareholders,

On behalf of the Managing Directors, I would like to welcome you to the 2023 Annual General Meeting of CompuGroup Medical.

It is great that many of you are joining us on the journey of driving digitization in healthcare. An exciting path on which we have embarked on and are already successfully driving change and progress. And there is still much more to achieve together.



” NOBODY SHOULD
SUFFER OR DIE
BECAUSE AT SOME
POINT MEDICAL
INFORMATION WAS
MISSING.

What began more than 35 years ago with the visionary foresight of our company founder, Frank Gotthardt, is now one of the leading software providers in the healthcare sector. What drove Frank Gotthardt back then is now our purpose and the motivation behind everything we do at CGM: Nobody should suffer or die because at some point medical information was missing.

This is the motivation for our employees to do their best every day, to go the extra mile for the actual everyday heroes in healthcare: doctors, dentists, pharmacists, paramedics, and all other healthcare practitioners.

We connect all practitioners in the healthcare sector, support them in their daily work and help our customers with the digital patient journey – for the benefit of the patients.

We focus on supporting healthcare providers in the best possible way with increasingly digitized processes, solutions and medical decision support tools.

We operate in an attractive growth area:

Attractive growth market e-health



The e-health sector is an attractive market in which new technologies enable entirely new possibilities for the targeted patient treatment against the background of rapidly advancing digitization. The entire health sector is changing: Think about the trend towards larger practices, the closing down of practices in rural areas, drug supply shortages or the financial challenges hospitals face. In addition, the population is ageing worldwide, resulting in rising healthcare costs. An increasing share of the gross domestic product is spent on healthcare. The digitization of the entire sector enables efficiency gains, an increased quality of healthcare and a reduction of costs.

CGM supports the healthcare sector with products and digital solutions in more than 50 countries worldwide. We contribute to shaping the rising connectivity in the healthcare system, which opens up new ways to help patients more efficiently, to provide care more timely and to speed up the healing process.

The need for new ways and solutions has also been addressed by numerous governments. As a result of the inefficiencies and cost overruns in the European healthcare market, many governments have launched extensive digitization initiatives.

CGM also supports those initiatives with a portfolio of technologically leading products. We act from a position of strength with a globally connected team:



With more than 9,000 employees worldwide, with locations in 20 countries, with highly motivated experts in the various regional healthcare systems, we develop new software and IT solutions for our customers and actively shape the change in the healthcare sector.

At this point, I would also like to thank all employees at CompuGroup Medical for their great commitment. Only due to their passionate work, always aligned with our corporate purpose, we have been able to write this success story together:



Over the past years, we have shown an impressive track record of growth.

A compound annual growth rate of more than 15 % in group revenues, supported by many successful and strategic company acquisitions and integrations.

The number of employees has almost doubled, we are much more international and act as one motivated and experienced team exceeding the revenue threshold of EUR 1.1 billion in the past year.



We achieved this thanks to numerous initiatives and projects, supporting healthcare providers. Let me highlight a few key projects in the year 2022:



The Hospital Future Act, the German governmental initiative for the modernization and digitization of hospitals, was launched in 2020, the first year of the pandemic. Since the beginning of this program, our colleagues in the hospital business have been busy helping our clients in this task. And while CGM's order intake related to the Hospital Futures Act reached EUR 25 million at the beginning of 2022, the amount rose steadily over the course of the year to around EUR 90 million. We have further raised the revenue target in connection with this governmental initiative and are now assuming EUR 110 million to EUR 130 million. We already recognized a small revenue impact and this will increase over the next few years.

As already mentioned, there is an increasing demand for connectivity of all healthcare practitioners. In Germany, the big connectivity project is the Telematics Infrastructure. And the so-called TI world is changing, too. Our development teams are already working on the next generation development of a high-speed connector, which can prospectively replace the physical connector box, and we are in the process of completing the development of a TI messenger. In 2022, the focus was still on the replacement of the first connector generation at the planned end of lifetime after five years. For security reasons, this first connector generation had to be replaced in order for our customers to remain connected to the telematics infrastructure and fully operational. We replaced over 20,000 hardware connectors in 2022. As of today, this number is over 30,000 in total. This was a quite an exercise for our team, and we would like to take this opportunity to thank the responsible colleagues, and also the doctors and dentists and

their helpful staff teams - without them this rollout would not have been possible so smoothly.



There are also relevant digitization initiatives in healthcare outside of Germany.

In France, for example, we successfully rolled out the first wave of the Ségur de la Santé program last year. We provided medical practices with state-of-the-art modules and digital tools and our French customers were supported in their plans to enable a digital patient journey.

We have also further developed our CLICKDOC platform, which is being used by more and more healthcare practitioners, also outside Germany. CLICKDOC is our cornerstone for the digital patient journey, from the patient's online appointment with the doctor, to the continuous availability of existing medication plans, to networking with other healthcare users.

Unfortunately, it is still often the case today that, for example, after a serious accident, upon arrival at the hospital the doctor first has to wait for a fax from the patient's general practitioner for information on current treatment or medication. With our CLICKDOC platform, this is possible at one glance -fast and paperless.

In order to further expand our position into the inpatient sector, we acquired a majority stake in the patient portal provider m.Doc in April this year. A strategic milestone, also with respect to the Hospital Future Act, where patient portals play an important role.

Dear shareholders, another trend fascinates many experts in the healthcare sector, in which we are also playing a pioneering role.

We support the healthcare sector with intelligent data solutions



Medicine increasingly complex and individualized



Physical medical care is being consistently reduced



Legally compliant support for physicians in medical decisions



New solutions through artificial intelligence

**Growing
market
potential**

The collection, processing and targeted use of anonymised medical data is a highly interesting growth market. Even more importantly, we contribute to the identification of rare diseases and detecting adverse drug reactions at an early stage. The data solutions we have developed, already support healthcare practitioners, and this market development is only just beginning and holds great potential.

We offer various product solutions and applications to enable doctors to respond to the changing healthcare market. Health professionals, under ever-increasing time pressure, usually have to react quickly, make sound decisions and prescribe the right medication so that every patient can be treated in the best possible way.

Our solutions, based on a wealth of medical data and supported by Artificial Intelligence, save the practitioner valuable time and provide legally compliant support for medical decisions.

And we are not resting on our strong market position. We want to address the growing market potential in the best possible way, and we further strengthened our position in the data business.

Strategic acquisitions in data business 2022




In the first half of 2022, we took a significant step towards expanding our portfolio of data solutions with the acquisition of INSIGHT Health. Just eight weeks after the closing of the transaction, we were able to offer the pharmaceutical industry a new joint product, developed by CGM and INSIGHT Health.

We then took the first decisive step towards internationalisation of the data business in the fourth quarter of 2022. After years of cooperation, we acquired a 20 percent stake in the Italian company New Line. Extensive market data is generated from a panel of around 12,000 pharmacies. These are of strategic importance for pharmaceutical companies, in the insurance industry and in the care sector.

At the end of last year, we announced the acquisition of parts of the business of the Gotthardt Health Group. With this acquisition, we added a highly developed data platform for data collection and processing to our portfolio, which enables doctors to analyse medical data and point out rare diseases during treatment. In addition, the Artificial Intelligence-based solution "medical brain" visualises insights, gained during treatment, including real-time evaluation of medical parameters to illustrate complex diagnostic features.

These acquisitions make an important contribution to reacting appropriately to future trends and to offering the right solutions for the changing demands of all players in the healthcare sector. But our success and attractive growth is not only based on acquisitions.



By focusing on our core competencies, supporting healthcare practitioners, bringing more digitization into the healthcare sector - and enabled by our growth investments in recent years - we successfully took organic growth to a new level.

With the start of our investment initiative end of 2020, we focused on building up the right resources for higher organic growth, and we were able to sustainably take organic growth to a new level in the following years.

2022 was the third year in a row with an organic growth rate significantly above the prior years' level.

This underlines that our investment initiative is bearing fruit.

Strategic acquisitions, strong organic growth combined with an excellent market position in an exciting growth market and a highly motivated team - ladies and gentlemen, those are the best reasons why I can now report on the results of a record year!

Overview group results 2022

in €m	Reported		Adjusted	
	2022	yoy	2022	yoy
Revenues	1,130	+10%	1,130	+10%
EBITDA	216	+1%	234	+4%
EBIT	104	+1%	148	+4%
Net income*	74	+7%	95	-8%
Earnings per share(€)**	1.40	+8%	1.80	-8%

In the year 2022, CompuGroup Medical exceeded the benchmark of one billion Euro for the second time in the company's history with a consolidated revenue of EUR 1.13 billion. This corresponds to an increase of 10 percent compared to the previous year.

Excluding the acquired businesses and the FX effects, CompuGroup Medical achieved a very good organic revenue growth of 4.1 percent compared to the previous year; adjusted for the one-off revenues from the connector software upgrade in the previous financial year in the Telematics Infrastructure, it would even have been 6.3 percent organic growth.

The operating result (EBITDA) for 2022, amounts to EUR 216 million. Adjusted for one-off effects EBITDA recorded EUR 234 million.

The adjusted earnings per share stood at EUR 1.80.

Let me please now move to the development of the individual segments.


Segments 2022

			Ambulatory Information Systems		Hospital Information Systems		Consumer & Health Management Information Systems		Pharmacy Information Systems	
Group			44 %		25 %		19 %		12 %	
	FY/22	yoy	FY/22	yoy	FY/22	yoy	FY/22	yoy	FY/22	yoy
Revenues (in €m)	1.130	+10%	502	+6% org. +1%	277	+8% org. +3%	220	+26% org. +12%	131	+10% org. +7%
EBITDA adjusted (in €m)	234	+4%	137	+15%	25	-41%	44	+11%	40	+18%
Margin	21%	-1ppt	27%	+2ppt	9%	-8ppt	20%	-3ppt	30%	+1ppt

In 2022, revenues increased strongly in all operating segments, and each of the operating segments posted organic growth.

Our growth investments, which we have made in the past years, are temporarily reflected in the margin development, as announced.

However, the positive effects resulting from the growth investments in a multi-year comparison clearly show that the path we have pursued is the right one:



In recent years, we have successfully raised both, revenue growth and revenue quality to a new level. Since 2020, revenues - supported by strategic acquisitions - have been increased by a CAGR of 16 percent. At the same time, as already mentioned, we have also improved the organic growth rates. For both categories, we have significantly raised the bar compared to previous years, and we are on a good path to maintain this in the long term to achieve our mid-term ambitions for 2025.

The revenue quality, reflected by recurring revenue, was also increased. This reflects both, the strength of our business model and the long-term nature of our customer relationships. We are well on track towards our ambition to increase the share of recurring revenues to over 70 percent by 2025.

Over recent years adjusted EBITDA has increased by an average of more than 4 percent per year, despite the higher investment in future growth.

Those of you who have been with us for some time know that CGM has always had high free cash flow in recent years. Last year's free cash flow is still at a high level, but requires a brief explanation.

Free cash flow and leverage



¹⁾ Leverage = Net debt (liabilities to banks and financial liabilities (incl. leasing liabilities according to IFRS 16) / cash and cash equivalents (with the exception of accounts under third-party management)) / EBITDA (LTM) adjusted for restructuring expenses plus pro rata EBITDA of newly acquired companies (Leverage 2021: EBITDA adjusted (LTM) plus pro rata EBITDA of newly acquired companies)


The free cash flow development in 2022 was influenced by advance payments in preparation for growth projects such as the connector hardware exchange in the Telematics Infrastructure, the preparation of projects related to the Hospital Futures Act and the Ségur program in France. In addition, free cash flow was impacted by payments related to management changes and restructuring. Another factor was delayed revenue recognition on some of our growth initiatives. This led to an adjustment of our free cash flow guidance after the third quarter of 2022.

In Q4 2022, free cash flow showed the expected rebound and ended the year with EUR 69 million, at the upper end of the adjusted guidance for 2022 of EUR 40million – EUR 70 million.

This had a direct impact on net debt, which is almost 10 percent higher, and a slightly higher leverage, which was also impacted by the acquisitions for future growth.

Both key figures, free cash flow and leverage, improved substantially in the first quarter of the current year.

However, these are not the only improvements we expect for the current year:



We again expect significant organic growth of around 5 percent in 2023.

We expect the adjusted EBITDA to be in the range of EUR 260 million to EUR 300 million which corresponds to an increase in a range of 11 to 28 percent compared to the previous year.

As you can see, we are still set for growth and profit increase - despite the current macroeconomic challenges!

Our highly motivated employees show great performance every day, and all of us at CGM are also aware of our social responsibility.

We have committed to climate neutrality. Thus, for the first time in CGM's history, our carbon footprint, was assessed and measured and we derived measures to contribute to a better future.

In 2022, we reached a share of women in management positions of 27 percent in the KGaA. In addition, we have established an internal women's network and organise female talent conferences to promote female leaders.

For the current year, we have set ourselves a major goal to increase employee satisfaction. We evaluate the commitment and satisfaction of our employees several times a year in order to derive appropriate projects and initiatives to strengthen employee loyalty in the long term. Subsequently, the respective managers implement specific measures to further improve the working atmosphere.

Because together as a strong team we follow our mission:

Our mission

**We create the future
of e-health.**



We create the future of e-health!

We are ready for an exciting 2023, in which we want to fulfil our mission a little more every day.

Dear shareholders, after my remarks on our operational activities of the past year, I would like to inform you about the share buyback program that expired last year.

Share buyback program

Share buyback program: January 3, 2022 - January 10, 2022

96,122 repurchased shares

€6,409,068.92 total amount (= €66.67 per share)

In addition to a dividend payment, we also want you, dear shareholders, to participate in the company's success in the form of share buyback programs.

Last year we did not make use of the authorisation to conduct share buyback programs. However, a share buyback program started on 26 November 2021 and ended on January 10, 2022. In the period from January 3, 2022 to January 10, 2022, a total of 96,122 shares were repurchased for an amount of EUR 6,409,068.92, which corresponds to an average price of EUR 66.67 per share.

Consolidated balance sheet 2022



Dear shareholders, we are pleased to present you again this year the balance sheet of a rock-solid company.

Compared to the end of the year 2021, the balance sheet total increased by more than EUR 140 million to EUR 1.944 billion. The assets have increased strongly compared to the end of the financial year 2021. Intangible assets are the largest item on the assets side of the consolidated balance sheet. These are primarily the hidden reserves from company acquisitions disclosed within the scope of purchase price allocations - i.e. the balance sheet value of customer relationships, order backlogs, software, trademark rights and goodwill.

At the end of the year, the equity ratio stood at 35 percent, a very solid figure and one percentage point above 2021.

Development of equity structure 2022



Overall, the group's equity increased strongly from EUR 612 million as of December 31, 2021 to EUR 674 million as of December 31, 2021. The consolidated net profit of EUR 74 million had a decisive impact here and was able to more than compensate for the dividend payment of about EUR 26 million.

Other changes, i.e. essentially changes in exchange rate and interest rate, as well as actuarial gains and losses, had a positive effect on equity last year, totalling EUR 22 million.

Dear shareholders, I would like to conclude with the appropriation of the net profits for the financial year 2022:

TOP 2: Appropriation of the net profits for financial year 2022

The general partner and the Supervisory Board propose that the net profits for financial year 2022 of EUR 105,329,940.47 be appropriated as follows:

Distribution of a dividend of EUR 0.50 per dividend-bearing no-par value share:	EUR 26,117,288.00
Credited to retained earnings:	EUR 0.00
Carryforward to new account:	EUR 79,212,652.47
Net profits:	EUR 105,329,940.47

Due to the positive development of the business and the unchanged positive outlook, the General Partner and the Supervisory Board propose to today's Annual General Meeting to resolve a dividend distribution in the amount of 50 Euro cents per dividend-bearing share for the financial year 2022.

This brings me to the end of my remarks on the 2022 financial year. Accompany us on our mission to create the future of digital healthcare.

Thank you for your attention and for the support of our company.

I hereby hand back to the Chairman of the Supervisory Board.